INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCERKhadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind M'rabti, Hassan Errihani.
Bevacizumab is a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor; it is actually approved for the treatment of unresectable, locally advanced and metastatic non-small cell lung cancer in association with chemotherapy and as maintenance therapy. Infection risk due to use of bevacizumab is a very rare event. Several cases of aspergillosis in patients treated with monoclonal antibodies have been reported, mostly following treatment with tumor necrosis factor alpha blockers. We present a case of a 60 year-old patient treated for stage IV non-small cell lung cancer, who has been diagnosed with invasive aspergillosis following bevacizumab treatment, and, we postulate that bevacizumab may contribute to this infection.
Invasive aspergillosis, Bevacizumab
Journal of Apitherapy
SUBMIT YOUR ARTICLE NOW